SCHEMBL22904384

SCHEMBL22904384

Nc1ccc(N2C[C@@H]3C(=O)NC(=O)[C@@H]3C2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DDB1 Q16531 4/20 0.43
CRBN Q96SW2 4/20 0.43
MAPT P10636 6/20 0.41
ALDH1A1 P00352 4/20 0.41
KDM4E B2RXH2 3/20 0.41
GAA P10253 3/20 0.41
HTT P42858 2/20 0.41
KMT2A Q03164 2/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
MEN1 O00255 1/20 0.41
NPC1 O15118 1/20 0.41
USP2 O75604 1/20 0.41
TP53 P04637 1/20 0.41
POLB P06746 1/20 0.41
THRB P10828 1/20 0.41
ALOX15 P16050 1/20 0.41
RECQL P46063 1/20 0.41
RAB9A P51151 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
HSD17B10 Q99714 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22904236 0.81 ACHE (0.39) MAPTALDH1A1KDM4EKMT2AMEN1
SCHEMBL22904243 0.81 NOTUM (0.42) MAPTALDH1A1KDM4EHTTKMT2A
SCHEMBL22904387 0.81 BPTF (0.50) DDB1CRBNMAPTKDM4EGAA
SCHEMBL22904386 0.80 CHRNA7 (0.42) ALDH1A1HTTKMT2AMEN1
SCHEMBL22904475 0.79 TRIM24 (0.50) MAPTALDH1A1KDM4EGAAKMT2A
SCHEMBL22904481 0.76 GPR119 (0.43) ALDH1A1MEN1POLB
SCHEMBL22904388 0.75 LTA4H (0.51) ALDH1A1ALOX15NPSR1LMNAMAPK1
SCHEMBL22904474 0.74 LIPE (0.46) L3MBTL1POLB
SCHEMBL6712337 0.71 MAPT (0.50) DDB1CRBNMAPTALDH1A1KDM4E
SCHEMBL22466171 0.70 MAPT (0.48) MAPTALDH1A1KDM4EGAAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021011631-A1 FUSED-GLUTARIMIDE CRBN LIGANDS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2021-01-21 WO disclosed
US-20160331734-A1 SUBSTITUTED N-ARYL PYRIDINONES AUSPEX PHARMACEUTICALS, INC. 2016-11-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160331734-A1 SUBSTITUTED N-ARYL PYRIDINONES COL1A1, COL2A1, COLGALT1 DDB1 2058/4885CRBN 1059/4885MAPT 3778/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.